GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (LTS:0LIF) » Definitions » Price-to-Owner-Earnings

Ultragenyx Pharmaceutical (LTS:0LIF) Price-to-Owner-Earnings : (As of Jun. 09, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Ultragenyx Pharmaceutical Price-to-Owner-Earnings?

As of today (2024-06-09), Ultragenyx Pharmaceutical's share price is $41.046. Ultragenyx Pharmaceutical does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Ultragenyx Pharmaceutical's Price-to-Owner-Earnings or its related term are showing as below:


LTS:0LIF's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.7
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-09), Ultragenyx Pharmaceutical's share price is $41.046. Ultragenyx Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-8.03. Therefore, Ultragenyx Pharmaceutical's PE Ratio for today is At Loss.

As of today (2024-06-09), Ultragenyx Pharmaceutical's share price is $41.046. Ultragenyx Pharmaceutical's EPS without NRI for the trailing twelve months (TTM) ended in was $-8.07. Therefore, Ultragenyx Pharmaceutical's PE Ratio without NRI for today is At Loss.


Ultragenyx Pharmaceutical Price-to-Owner-Earnings Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Price-to-Owner-Earnings Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ultragenyx Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ultragenyx Pharmaceutical's Price-to-Owner-Earnings

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultragenyx Pharmaceutical's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's Price-to-Owner-Earnings falls into.



Ultragenyx Pharmaceutical Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Ultragenyx Pharmaceutical's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=41.046/-7.96
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ultragenyx Pharmaceutical  (LTS:0LIF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Ultragenyx Pharmaceutical Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultragenyx Pharmaceutical (LTS:0LIF) Business Description

Traded in Other Exchanges
Address
60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Ultragenyx Pharmaceutical (LTS:0LIF) Headlines

No Headlines